Polyneuron Raises CHF22.5 Million in Series A to Advance Novel Therapies for Autoimmune Diseases
BASEL, Switzerland--(BUSINESS WIRE)--Mar 28, 2019--Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases…
